CA3177779A1 - New compositions and methods of treating covid-19 disease - Google Patents

New compositions and methods of treating covid-19 disease

Info

Publication number
CA3177779A1
CA3177779A1 CA3177779A CA3177779A CA3177779A1 CA 3177779 A1 CA3177779 A1 CA 3177779A1 CA 3177779 A CA3177779 A CA 3177779A CA 3177779 A CA3177779 A CA 3177779A CA 3177779 A1 CA3177779 A1 CA 3177779A1
Authority
CA
Canada
Prior art keywords
patients
composition
covid
plerixafor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177779A
Other languages
English (en)
French (fr)
Inventor
Patrick Berger
Isabelle Dupin
Renaud PREVEL
Chloe James
Pierre-Olivier Girodet
Keren BISMUTH
Revital RATTENBACH
Jerome Breton
Francois Trottein
Valentin SENCIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4living Biotech
Centre Hospitalier De Bordeaux
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Bordeaux
Universite de Lille
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3177779A1 publication Critical patent/CA3177779A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3177779A 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease Pending CA3177779A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173595.8A EP3906922A1 (en) 2020-05-07 2020-05-07 New compositions and methods of treating covid-19 disease
EP20173595.8 2020-05-07
PCT/EP2021/061919 WO2021224356A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease

Publications (1)

Publication Number Publication Date
CA3177779A1 true CA3177779A1 (en) 2021-11-11

Family

ID=70617050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177779A Pending CA3177779A1 (en) 2020-05-07 2021-05-05 New compositions and methods of treating covid-19 disease

Country Status (9)

Country Link
US (1) US20230157994A1 (https=)
EP (2) EP3906922A1 (https=)
JP (1) JP2023539542A (https=)
KR (1) KR20240073720A (https=)
CN (1) CN116133657A (https=)
AU (1) AU2021269090A1 (https=)
BR (1) BR112022022578A2 (https=)
CA (1) CA3177779A1 (https=)
WO (1) WO2021224356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
JP2023524522A (ja) * 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
WO2022197625A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197627A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197626A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用
WO2024092069A1 (en) * 2022-10-26 2024-05-02 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors for treatment of neurological diseases
CN121039852A (zh) 2023-06-07 2025-11-28 株式会社Lg新能源 锂金属电池及包含该锂金属电池的电池模组和电池包

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TW200811138A (en) * 2006-06-12 2008-03-01 Pfizer Prod Inc Pharmaceuticals
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CN110982945B (zh) * 2020-03-04 2020-06-09 珠海丽珠试剂股份有限公司 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法

Also Published As

Publication number Publication date
EP4146195A1 (en) 2023-03-15
JP2023539542A (ja) 2023-09-15
CN116133657A (zh) 2023-05-16
AU2021269090A1 (en) 2022-12-01
KR20240073720A (ko) 2024-05-27
EP3906922A1 (en) 2021-11-10
WO2021224356A1 (en) 2021-11-11
US20230157994A1 (en) 2023-05-25
BR112022022578A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
US20230157994A1 (en) New compositions and methods of treating covid-19 disease
Zawilska et al. COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment.
US20210309733A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20210346357A1 (en) Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compound
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
Ali et al. The role of tocilizumab in cytokine storm and improving outcomes in COVID-19
US20220363746A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
AU2021247258A1 (en) Anti-CD6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including COVID-19
JP5172679B2 (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
US20240317846A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230192872A1 (en) Tocilizumab for the treatment of viral infections
Yakut et al. What we know about COVID-19 and its treatment
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
Roche et al. Therapeutics in hospitalised adult patients with COVID-19
KR20230041097A (ko) SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
US20230109208A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
Sodani Potential pharmacological Therapeutics options for COVID-19
Sheha et al. Immune Insights: Profiling the Response in COVID-19 Affected Individuals
Sriram et al. Drug Repurposing Studies in the Progress to Combat COVID-1
Rezagholizade A comprehensive review on sarilumab in COVID-19
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
Nirola et al. Management of Various Covid-19 Patients and Its Periodontal Considerations

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251021

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203